BUDGET IMPACT OF SUBCUTANEOUS IMMUNOGLOBULIN 20% (IGPRO20) IN CIDP FROM A GERMAN STATUTORY HEALTH INSURANCE PERSPECTIVE
Author(s)
Batyrkhan Kuatov, MA1, Laurence UNDREINER, MSc2, Leonie Schumacher, MSc3, Isabell Kaufhold, MSc3, Caroline Rupprecht, MSc3, Nhu Ngoc Le, BS3, Daniel Lewkowicz, MSc3, Florian Kron, PhD3, Thomas Hardt, PhD4.
1Director HEOR, Global Market Access, CSL Behring, Bern, Switzerland, 2CSL Behring, Paris, France, 3VITIS Healthcare Group, Cologne, Germany, 4Vifor Pharma Deutschland GmbH, Munich, Germany.
1Director HEOR, Global Market Access, CSL Behring, Bern, Switzerland, 2CSL Behring, Paris, France, 3VITIS Healthcare Group, Cologne, Germany, 4Vifor Pharma Deutschland GmbH, Munich, Germany.
OBJECTIVES: Subcutaneous immunoglobulin (SCIg) therapy is increasingly used as an alternative to intravenous immunoglobulin (IVIg) in chronic inflammatory demyelinating polyneuropathy (CIDP), enabling home-based administration, improving patient convenience and potentially reducing costs for the German Statutory Health Insurance (SHI). This study assessed the budget impact of increased market share of IgPro20 compared with facilitated SCIg (fSCIg, 10%) and a comparator basket of IVIg products over a 5-year horizon.
METHODS: A prevalence-based budget impact model was developed from the SHI perspective for 2026-2030. The treated CIDP population was estimated using published epidemiological data, market research forecasts, and German SHI statistics. Annual per-patient costs included drug acquisition (Lauer-Taxe, May 2026), physician services, consumables, pump provision, and adverse-event (AE) management. All costs were adjusted to 2026 Euros. Uncertainty was explored using scenario and sensitivity analyses.
RESULTS: Annual per-patient costs were €111,223 for IgPro20, compared with €149,889 for fSCIg and €138,234 for the IVIg basket, resulting in savings of €38,665 and €27,011 per patient per year, respectively. Drug acquisition costs were the main cost driver (−€39,058 vs. fSCIg; −€28,025 vs. IVIg), while administration costs were €395 higher for IgPro20 versus fSCIg. AE costs were comparable between IgPro20 and fSCIg but favored IgPro20 by €188 per patient annually versus IVIg. Accelerated IgPro20 uptake generated cumulative SHI savings of approximately €30.6 million over 5 years.
CONCLUSIONS: Increasing IgPro20 use in CIDP may generate substantial savings for the German SHI, primarily through lower drug acquisition costs, while supporting efficient resource allocation and patient preference alignment for self-administered SCIg.
METHODS: A prevalence-based budget impact model was developed from the SHI perspective for 2026-2030. The treated CIDP population was estimated using published epidemiological data, market research forecasts, and German SHI statistics. Annual per-patient costs included drug acquisition (Lauer-Taxe, May 2026), physician services, consumables, pump provision, and adverse-event (AE) management. All costs were adjusted to 2026 Euros. Uncertainty was explored using scenario and sensitivity analyses.
RESULTS: Annual per-patient costs were €111,223 for IgPro20, compared with €149,889 for fSCIg and €138,234 for the IVIg basket, resulting in savings of €38,665 and €27,011 per patient per year, respectively. Drug acquisition costs were the main cost driver (−€39,058 vs. fSCIg; −€28,025 vs. IVIg), while administration costs were €395 higher for IgPro20 versus fSCIg. AE costs were comparable between IgPro20 and fSCIg but favored IgPro20 by €188 per patient annually versus IVIg. Accelerated IgPro20 uptake generated cumulative SHI savings of approximately €30.6 million over 5 years.
CONCLUSIONS: Increasing IgPro20 use in CIDP may generate substantial savings for the German SHI, primarily through lower drug acquisition costs, while supporting efficient resource allocation and patient preference alignment for self-administered SCIg.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE103
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Rare & Orphan Diseases